Warp Sciences: Ex-OpenAI executive wants robots to do medicinal chemistry

What's new

Kevin Weil, formerly OpenAI's head of science and chief product officer, has launched the AI startup Warp Sciences. It was announced on October 22, 2026. The company has raised $215 million in a so-called Series A (an early, large funding round) at a post-money valuation of $865 million. The round was led by Lightspeed Venture Partners, and other investors include IVP, Premji Invest and Lux Capital. One source also mentions Mayfield and Menlo Ventures, but the sources do not agree on the full list.

In August 2026, it was reported that Weil was raising $150 million at a valuation of at least $750 million for an AI science startup that was then in stealth (meaning without public mention). The launch now cites $215 million at $865 million. The company has not explained the difference.

Weil is CEO. The cofounders are DJ Patil, who was the White House's first chief data scientist, Manohar Paluri, who is chief technology officer and a former vice president at Meta, and Solomon Reisberg, formerly of Terremoto Biosciences. The team is small, at around 20 employees.

What's clever

Warp wants to automate the chemistry work involved in optimizing a drug. This means making hundreds or thousands of variants of a molecule to make it more effective and cause fewer side effects. It is heavy, repetitive lab work.

The method is unusual: Chemists wear cameras and sensor gloves that measure pressure while they work. The recordings become training data for the company's own AI models, which are meant to teach robots the manual dexterity of the lab. Once the robots are trained, the plan is for them to work around the clock, making and testing compounds that researchers have selected.

Weil says AI has significantly accelerated software development and mathematics, but has not yet had the same effect in the physical sciences.

Cheaper or better?

It is too early to say. No customers, throughput figures, accuracy figures or data on synthesized compounds have been published, and there is no independent verification of the technology. Pricing has not been disclosed.

The business model is preclinical research services in the US. To begin with, experienced chemists carry out customers' projects, and the automation will be built out gradually to cover more complex tasks. Warp is targeting work that pharmaceutical companies often send to Chinese contract firms such as WuXi AppTec. The goal is to move it to the US and make drug development less vulnerable to geopolitical supply risks.

The field already includes Chai Discovery, which has raised $400 million, and Medra, which is building autonomous robotic labs. There is no direct comparison with them on price or performance.

What it's good for

Warp is not a tool you can download. It is a service aimed at pharmaceutical companies that need chemists to make and test many molecule variants in the early phases, before a compound is tested in humans. The sources do not say whether the service will be available in Denmark or the EU, and it appears to be aimed at the US.

For ordinary Danes, the impact is indirect. If it succeeds, new drugs could eventually be developed faster. For now, it is an expensively funded plan, not a documented result.